I am a neuro-oncologist who specializes in the care of patients with brain tumors and the neurologic complications of cancer. My team of physicians, nurses, research staff, and administrative support works with patients to deliver effective and compassionate specialized care in the treatment of both primary brain tumors (including glioblastomas, anaplastic gliomas, low-grade gliomas, ependymomas, and meningiomas) as well as brain metastases that have spread from other solid cancers the body.
Read more Read less
I am currently conducting clinical trials and research for glioblastomas and other primary brain tumors in both the upfront and recurrent settings. My research also focuses on the treatment of patients with both benign and aggressive meningiomas, specifically investigating chemotherapy and molecularly targeted therapy when surgery and radiation are not an option.
I also serve as co-director of our Neuro-Oncology Fellowship Program and have a firm commitment to the education and training of our fellows and preparing them for a successful future career in neuro-oncology.
- Clinical Expertise: Neuro-Oncology; Adult Brain Tumors
- Languages Spoken: English
- Education: MD, New York University
- Residencies: Neurology - New York University School of Medicine
- Fellowships: Neurology - Memorial Sloan Kettering Cancer Center
- Board Certifications: Neurology
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Read more Read less
Clinical Trials Led by Thomas J. Kaley
Clinical Trials Co-Investigated by Thomas J. Kaley
- A Phase I Study of Varlilumab plus Nivolumab Immunotherapy in Patients with Advanced Solid Tumors
- A Phase II Study Comparing Higher-Dose with Standard-Dose Radiotherapy for Glioblastoma
- A Phase II Study of Abemaciclib for Patients with Recurrent Glioblastoma
- A Phase II Study of PT2385 for Patients with Recurrent Glioblastoma
- A Phase II Study of Temozolomide and Radiation Therapy with Nivolumab Immunotherapy or a Placebo in Patients Newly Diagnosed with Glioblastoma
- A Phase III Study of Armodafinil versus Placebo to Reduce Cancer-Related Fatigue in Patients with High-Grade Glioma
- A Phase III Study of Radiation Therapy with Temozolomide or Nivolumab Immunotherapy in Patients Newly Diagnosed with Glioblastoma
- A Pilot Study of Meclofenamate to Treat Cancer that Has Spread to the Brain
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more